CAS 866409-68-9

QLT0267

CAS: 866409-68-9

QLT0267 is an inhibitor targeting integrin-linked kinase (ILK; IC50= 26 nM), showing over 10-fold selectivity against cyclin-dependent kinases 1, 2, and 5 (Cdk1, Cdk2, and Cdk5), and over 1,000-fold selectivity against C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2) at a concentration of 10 mg/ml. This compound effectively inhibits the proliferation of NPA187 papillary thyroid cancer cells with an IC50 of approximately 3 µM and induces apoptosis in NPA187, DRO, and K4 cancer cell lines. In vivo studies reveal that QLT0267, administered at 100 mg/kg, significantly reduces tumor growth in a DRO mouse xenograft model and diminishes both tumor volume and intratumoral vascularization in a U87MG glioblastoma mouse xenograft model, showcasing its potential for therapeutic applications in cancer treatment.

Formula: C₁₀H₁₂N₆O

Color and Shape: Solid

Molecular weight: 232.24

Ref: TM-T84998

QLT0267

CAS: 866409-68-9

QLT0267 is a peptide that belongs to the class of activators. It has been shown to activate a number of ion channels and receptors, including potassium channels, G-protein coupled receptors, and ligand-gated ion channels. QLT0267 is also an inhibitor of protein interactions, such as receptor-ligand binding and antibody-antigen binding. This compound is highly purified with 98% purity. It is not known whether QLT0267 binds to any other proteins in addition to the ones mentioned above.

Formula: C₁₀H₁₂N₆O

Purity: Min. 95%

Molecular weight: 232.24 g/mol

Ref: 3D-RJB40968